Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis-Reference-Cited by-同舟云学术

Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis

Published:2019-09-28 Issue:1 Volume:36 Page:169-176
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Wu Jashin J.¹,Pelletier Corey²,Ung Brian²,Tian Marc²

Affiliation:

1. Dermatology Research and Education Foundation, Irvine, CA, USA;

2. Celgene Corporation, Summit, NJ, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2019.1668204

Reference32 articles.

1. Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015

2. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

3. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

4. The Epidemiology of Psoriatic Arthritis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic;Dermatology and Therapy;2023-07-01

2. Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey;Dermatology and Therapy;2023-05-31

3. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies;Journal of Dermatological Treatment;2023-03-03

4. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial;Annals of the Rheumatic Diseases;2021-11-23

5. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study;Advances in Therapy;2021-03-23